Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding AG    ROG   CH0012032048


News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Roche : faces UK pricing row over multiple sclerosis drug Ocrevus

share with twitter share with LinkedIn share with facebook
share via e-mail
09/09/2018 | 07:14pm EDT
Logo of Swiss drugmaker Roche is seen at its headquarters in Basel

LONDON (Reuters) - Roche faces a fresh row over drug pricing in Britain, following a decision by the body responsible for medicine use within the state health service not to approve its drug Ocrevus for treating a highly disabling form of multiple sclerosis (MS).

In June, the National Institute for Health and Care Excellence (NICE) endorsed Ocrevus for relapsing-remitting MS - the most common type of the disease - but it has now rejected it for the rarer and more severe primary-progressive form of MS.

Ocrevus is the only available treatment for primary-progressive MS (PPMS), while there are several drugs for relapsing-remitting MS (RRMS), and Roche UK general manager Richard Erwin said Monday's decision was "devastating news" for patients.

It is not the first time the Swiss drugmaker has clashed with NICE, which determines if drugs are cost-effective enough to be used in the National Health Service (NHS) in England and Wales.

Roche has also battled to get a number of its cancer drugs approved by NICE in the past, prompting Chief Executive Severin Schwan to brand Britain's health system as "stupid" three years ago https://uk.reuters.com/article/us-roche-cancer-britain/roche-ceo-attacks-britains-stupid-cancer-drug-system-idUKKCN0R81J620150908.

In the case of Ocrevus, Roche said it had reached a stalemate because the authorities were not allowed to even consider a confidential discounted price for using the drug in PPMS that was different from the RRMS price.

That is a problem because the evidence showing the benefit of Ocrevus in PPMS is not as compelling as in RRMS, so a lower price would be needed to reach NICE cost-effectiveness thresholds.

The restriction meant NICE had to consider the existing RRMS approved price for the PPMS indication and this was deemed too expensive. In a statement, NICE said the size and duration of the drug's benefits in PPMS were uncertain and it could not be considered an acceptable use of NHS resources.

Worldwide, Ocrevus has proved to be a big commercial success for Roche, with sales topping $1 billion in the first half of 2018, and the company said it hoped an agreement could be reached for its use within the NHS.

"Roche is confident that given the flexibility to offer an indication-specific price, we will be able to offer a price that is deemed cost-effective for PPMS," the company said.

(Reporting by Ben Hirschler; Editing by Mark Potter)

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ROCHE HOLDING AG
04:57aROCHE : Invitation to Roche's live audio webcast on Gazyva in lupus nephritis pr..
10/14EUROPE : European stocks hit pause as trade doubts linger
10/14GLOBAL MARKETS LIVE : Sophos, Mercedes, Facebook, Boeing…
10/14ROCHE : Phase III PEMPHIX Study Shows Genentech's Rituxan Superior to Mycophenol..
10/14ROCHE : Phase III PEMPHIX study shows Roche's MabThera/Rituxan (rituximab) super..
10/14ROCHE : Phase III PEMPHIX study shows Roche's MabThera/Rituxan (rituximab) super..
10/09REMINDER : Invitation to Roche's 9 Months Sales 2019 Audio Webcast and Conferenc..
10/08GLOBAL MARKETS LIVE : Nissan, Airbus, Samsung, Wirecard…
10/08ROCHE : Invitation to Roche's Virtual Early Drug Development pRED Event 2019
10/07Gilead Sciences Names Merdad Parsey Chief Medical Officer
More news
Financials (CHF)
Sales 2019 61 762 M
EBIT 2019 22 012 M
Net income 2019 14 552 M
Debt 2019 3 174 M
Yield 2019 3,20%
P/E ratio 2019 17,4x
P/E ratio 2020 16,9x
EV / Sales2019 4,04x
EV / Sales2020 3,89x
Capitalization 246 B
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 303,64  CHF
Last Close Price 288,20  CHF
Spread / Highest target 23,5%
Spread / Average Target 5,36%
Spread / Lowest Target -21,9%
EPS Revisions
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING AG18.41%247 003
JOHNSON & JOHNSON0.01%346 602
MERCK AND COMPANY10.38%215 942
PFIZER-17.27%199 726
NOVARTIS14.95%199 287
NOVO NORDISK AS17.25%121 422